ArticleHepatology communications2026
Thyroid hormone acts independently of the thyroid hormone receptor beta in hepatocytes to improve systemic insulin sensitivity.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin resistance plays a key role in the development of type 2 diabetes and predates the development of frank hyperglycemia. Thyroid hormone (TH) signaling plays a critical role in glucose homeostasis, as both hyperthyroidism and hypothyroidism have been linked to the development of insulin resistance and diabetes. The mechanism behind the effects of TH action on insulin sensitivity is incompletely understood, but the liver is thought to play a key role. Indeed, resmetirom, a selective thyroid hormone receptor beta (THRβ) agonist, has recently been approved for treatment of liver fibrosis, and more THRβ agonists are currently in phase 2-3 clinical trials for use in metabolic dysfunction-associated fatty liver disease. As insulin resistance is closely associated with this disease, it is crucial that we understand the role of hepatic THRβ in glucose homeostasis. Thus, we hypothesized that TH, acting via the THRβ, is a key regulator of hepatic glucose metabolism.
methodsIn wild-type (WT) and liver-specific THRβ knock-out (L-TRBKO) mice we analyzed the effect of changes in thyroid status and diet on glucose homeostasis and insulin signaling. Mice were assessed under basal conditions on a chow fed diet, under hypothyroid conditions using a propylthiouracil/low iodine diet with and without T3 treatment and following a high-fat diet. We measured glucose tolerance, hepatic insulin signaling, liver histology, energy expenditure and skeletal muscle metabolism. In high-fat diet fed WT and L-TRBKO mice we addidionally analyzed the effect of a single i.p. injection of T3. Finally we studied insulin signaling in human induced pluripotent stem cells differentiated to hepatocytes (iHeps) both with and without THRβ expression.
resultsIn contrast to our hypothesis, we found that insulin signaling in mice was not impacted by the selective deletion of THRβ only in hepatocytes. Both WT and L-TRBKO mice have similar glucose homeostasis under basal conditions and developed hyperglycemia on a high-fat diet. Further, a single dose of T3 administered to high-fat diet fed insulin-resistant mice improves insulin sensitivity to the levels of control chow-fed mice in both WT and L-TRBKO male mice. This single dose of T3 also increased glucose transporter expression in skeletal muscle. In iHeps, THRβ1 was not required to activate insulin signaling, and T3 treatment did not affect insulin signaling.
conclusionT3 signaling impacts glucose homeostasis independently of its actions through the THRβ1 in hepatocytes in both a murine and human model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.